INNOVATIVE
LAB FOR
RESPONSIVE
CARE

A GLYCO-HUMANIZED ANTIBODY PLATFORM WITH EMBEDDED TECHNOLOGY THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy
XENOTHERA is addressing unmet medical needs with proprietary Glyco-Humanized Antibodies:
Genetic engineering of the bioproduction Immunogen strategy and optimization Enhanced therapeutic efficiency of GH-pAb mix Pharmaceutical development done and stability data for more than 3 years Translational development program experience
Therapeutic domains:

Immunology
Solid organ transplantation
Viral infections
Multi-Drug Resistant Bacteria
Oncology
Others

Executive team

A clinical stage Biotech

An agile company with a fast-paced development

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. We develop innovative  approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 8 years, XENOTHERA has brought to clinic LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. and XAV19, its anti-COVID treatment for patients with moderate disease. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.

Pipeline
Products in development

Latest
News

contact@xenothera.com
Publié par contact@xenothera.com
11 mars 2022

[Newsletter] XENONEWS

February 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More
contact@xenothera.com
Publié par contact@xenothera.com
28 janvier 2021

[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody

# Download our press information (english version) # Télécharger notre communiqué de...

More
contact@xenothera.com
Publié par contact@xenothera.com
11 mars 2022

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

January 2022. # Download our press information (english version) # Télécharger notre...

More
XENOTHERA’s worldwide network
XENOTHERA is built on a worldwide network of scientific & medical collaboration.

Related
scientific papers

 

XENOTHERA is a start-up in biotechnology, specialized in immunology, transplantation,
infectious diseases and oncology.

Investors already trusted us since creation by funding the company more than 30M€,

completed with 15M€ non-dilutive financing. Our products will offer a substantial patient benefit
and address unsolved major public health issues

To contact us, use the form or see our full contact below:

XENOTHERA

1 rue Vauban – 44000 Nantes – France

To work with us: careers@xenothera.com

Press Contact: IZsoGOOD – Ingrid Zémor – xenothera@izsogood.co

  • Home
  • Expertise
  • Team
  • About
  • About pipeline
  • News
  • Partnerships
  • Publications
  • Contact form
  • Contact